Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 133

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 133
---
 any other prospectus filed pursuant to the provisions of Rule 462 under the Securities
Act.

Pursuant to the requirements
of the Securities Act of 1933, this amendment to the prospectus on Form F-1 has been signed by the following persons in the capacities
and on the dates indicated.

| Signature                         
 /s/ Alexander Zwyer               |     | Title                                               
 Chief Executive Officer and Director                |     | Date               
 September 25, 2025 |
|:----------------------------------|:----|:----------------------------------------------------|:----|:-------------------|
| Alexander Zwyer                   |     | -Principal Executive Officer                        |     |                    |
| /s/ Nicole Fernandez–McGovern     |     | Chief Financial Officer and Chief Operating Officer |     | September 25, 2025 |
| Nicole Fernandez–McGovern         |     | -Principal Financial and Accounting Officer         |     |                    |
| /s/ Ronald Hafner                 |     | Chairman of the Board of Directors                  |     | September 25, 2025 |
| Ronald Hafner                     |     |                                                     |     |                    |
| /s/ Florence Allouche Aknin       |     | Director                                            |     | September 25, 2025 |
| Florence Allouche Aknin           |     |                                                     |     |                    |
| /s/ Gian-Marco Rinaldi de la Cruz |     | Director                                            |     | September 25, 2025 |
| Gian-Marco Rinaldi de la Cruz     |     |                                                     |     |                    |
| /s/ Olivier Samuel                |     | Director                                            |     | September 25, 2025 |
| Olivier Samuel                    |     |                                                     |     |                    |

<div align='center'>II-7

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</div>

Pursuant to the Securities
Act of 1933, as amended, the undersigned, Puglisi & Associates, the duly authorized representative in the United States of NLS Pharmaceutics
Ltd., has signed this prospectus on September 25, 2025.

| PUGLISIGI & ASSOCIATES |                       |
| By:                    | /s/ Donald J. Puglisi |
| Name:                  | Donald J. Puglisi     |
| Title:                 | Managing Director     |

<div align='center'>II-8</div>